[1]GLINKA A,WU W,DELIUS H,et al.Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction［J］.Nature,1998,391(6665):357-362.
[2] PINZONE JJ,HALL BM,THUDI NK,et al.The role of Dickkopf-1 in bone development,homeostasis,and disease［J］.Blood,2009,113(3):517-525.
[3] HUANG Y,LIU L,LIU A.Dickkopf-1:Current knowledge and related diseases［J］.Life Sci,2018,209:249-254.
[4] D'AMICO L,MAHAJAN S,CAPIETTO AH,et al.Dickkopf-related protein 1(Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer［J］.J Exp Med,2016,213(5):827-840.
[5] PARSONS MJ,TAMMELA T,DOW LE.WNT as a driver and dependency in cancer［J］.Cancer Discov,2021,11(10):2413-2429.
[6] KIKUCHI A,MATSUMOTO S,SADA R.Dickkopf signaling,beyond Wnt-mediated biology［J］.Semin Cell Dev Biol,2022,125:55-65.
[7] IGUCHI K,SADA R,MATSUMOTO S,et al.DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness［J］.Cancer Sci,2023,114(5):2063-2077.
[8] YAO L,ZHANG D,ZHAO X,et al.Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype［J］.J Cell Mol Med,2016,20(9):1673-1685.
[9] QIAO R,ZHONG R,CHANG Q,et al.Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases［J］.Oncotarget,2017,8(45):79469-79479.
[10] KASOHA M,BOHLE RM,SEIBOLD A,et al.Dickkopf-1(Dkk1) protein expression in breast cancer with special reference to bone metastases［J］.Clin Exp Metastasis,2018,35(8):763-775.
[11] KASOHA M,STEINBACH AK,BOHLE RM,et al.Dkk1 as a prognostic marker for neoadjuvant chemotherapy response in breast cancer patients［J］.Cancers(Basel),2024,16(2):419.
[12] ZHAO C,LIU L,HE Q,et al.Dickkopf-1 is an immune infiltration-related prognostic biomarker of head and neck squamous cell carcinoma［J］.Aging(Albany NY),2024,16(4):3837-3855.
[13] FENG Y,ZHANG Y,WEI X,et al.Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma［J］.Cancer Biomark,2019,24(2):195-201.
[14] CAO M,WANG Y,LU G,et al.Classical angiogenic signaling pathways and novel anti-angiogenic strategies for colorectal cancer［J］.Curr Issues Mol Biol,2022,44(10):4447-4471.
[15] WISE DR,SCHNEIDER JA,ARMENIA J,et al.Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer［J］.JCO Precis Oncol,2020,4:PO.20.00097.
[16] SHI T,ZHANG Y,WANG Y,et al.DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer［J］.Cancer Immunol Res,2022,10(12):1506-1524.
[17] LI J,ZHANG Y,YE F,et al.DKK1 promotes epithelial-mesenchymal transition and cisplatin resistance in gastric cancer via activation of the PI3K/AKT pathway［J］.Cancers(Basel),2023,15(19):4756.
[18] SUI Q,LIU D,JIANG W,et al.Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer［J］.J Immunother Cancer,2021,9(3):e001498.
[19] YE X,LIU J,QUAN R,et al.DKK1 affects survival of patients with head and neck squamous cell carcinoma by inducing resistance to radiotherapy and immunotherapy［J］.Radiother Oncol,2023,181:109485.
[20] YANG RH,QIN J,CAO JL,et al.Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma［J］.Biochem Pharmacol,2023,208:115378.
[21] WU M,ZHANG X,ZHANG W,et al.Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis［J］.Nat Commun,2022,13(1):1371.
[22] MOON SJ,CHOI HJ,KYE YH,et al.CTTN overexpression confers cancer stem cell-like properties and trastuzumab resistance via DKK-1/WNT signaling in HER2 positive breast cancer［J］.Cancers(Basel),2023,15(4):1168.
[23] ZHUANG X,ZHANG H,LI X,et al.Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1［J］.Nat Cell Biol,2017,19(10):1274-1285.
[24] YUAN S,HOGGARD NK,KANTAKE N,et al.Effects of Dickkopf-1(DKK-1) on prostate cancer growth and bone metastasis［J］.Cells,2023,12(23):2695.
[25] XU Y,HU J,LYU Q,et al.Endometrium-derived mesenchymal stem cells suppress progression of endometrial cancer via the DKK1-Wnt/β-catenin signaling pathway［J］.Stem Cell Res Ther,2023,14(1):159.
[26]ZHOU HJ,ZHOU M.The diagnostic value of serum DKK1 in endometrial cancer［J］.Modern Oncology，2018，25（20）：3293-3296.
[27] GAN DX,WANG YB,HE MY,et al.Lung cancer cells-controlled Dkk-1 production in brain metastatic cascade drive microglia to acquire a pro-tumorigenic phenotype［J］.Front Cell Dev Biol,2020,8:591405.
[28] LI X,WANG J,ZHU S,et al.DKK1 activates noncanonical NF-κB signaling via IL-6-induced CKAP4 receptor in multiple myeloma［J］.Blood Adv,2021,5(18):3656-3667.
[29] GIRALT I,GALLO-OLLER G,NAVARRO N,et al.Dickkopf-1 inhibition reactivates Wnt/β-Catenin signaling in rhabdomyosarcoma,induces myogenic markers in vitro and impairs tumor cell survival in vivo［J］.Int J Mol Sci,2021,22(23):12921.
[30] DI M,ZHANG Y,ZENG R,et al.The pro-angiogenesis effect of miR33a-5p/Ets-1/DKK1 signaling in ox-LDL induced HUVECs［J］.Int J Biol Sci,2021,17(15):4122-4139.
[31] WANG Y,YU H,XIE X,et al.Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway［J］.Oncogene,2021,40(25):4324-4337.
[32] ZHAI J,CHEN H,WONG CC,et al.ALKBH5 drives immune suppression via targeting AXIN2 to promote colorectal cancer and is a target for boosting immunotherapy［J］.Gastroenterology,2023,165(2):445-462.
[33] ZHANG Y,LIANG K,ZHOU X,et al.Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer［J］.Cancer Sci,2023,114(7):2798-2809.
[34] SIMIC MK,MOHANTY ST,XIAO Y,et al.Multi-targeting DKK1 and LRP6 prevents bone loss and improves fracture resistance in multiple myeloma［J］.J Bone Miner Res,2023,38(6):814-828.
[35] NAGOYA A,SADA R,KIMURA H,et al.CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer［J］.Transl Lung Cancer Res,2023,12(3):408-426.
[36] HAAS MS,KAGEY MH,HEATH H,et al.mDKN-01,a novel Anti-DKK1 mAb,enhances innate immune responses in the tumor microenvironment［J］.Mol Cancer Res,2021,19(4):717-725.
[37] BETELLA I,TURBITT W J,SZUL T,et al.Dkn-01:A promising strategy for targeting the Wnt pathway in ovarian cancer［J］.Gynecologic Oncology,2019,154:55.
[38] JARMAN EJ,HORCAS-LOPEZ M,WADDELL SH,et al.DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01［J］.Liver Int,2023,43(1):208-220.
[39] AREND R,DHOLAKIA J,CASTRO C,et al.DKK1 is a predictive biomarker for response to DKN-01:Results of a phase 2 basket study in women with recurrent endometrial carcinoma［J］.Gynecol Oncol,2023,172:82-91.
[40] KLEMPNER SJ,BENDELL JC,VILLAFLOR VM,et al.Safety,efficacy,and biomarker results from a phase Ib study of the anti-DKK1 antibody DKN-01 in combination with pembrolizumab in advanced esophagogastric cancers［J］.Mol Cancer Ther,2021,20(11):2240-2249.
[41] QIAN J,WANG Q,XIAO L,et al.Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers［J］.J Immunother Cancer,2024,12(1):e008145.